31Oct
31Oct
CytoAgents Receives Fourth Grant From National Institutes of Health to Advance Research on Cytokine Release Syndrome
PITTSBURGH--(BUSINESS WIRE)--CytoAgents, Inc., a clinical-stage biotechnology company developing a safe and effective preventative treatment for cytokine release syndrome (CRS) and the neurotoxicity immune effector cell-associated neurotoxicity syndrome (ICANS), announced today that it has been awarded a $2.25 million National Institutes of Health (NIH) grant, the fourth NIH grant totaling $7.85 million in five years. Read More>>
24Oct
New ScorePlay and Wasabi Technologies partnership gives sports organizations the ultimate platform for smarter, faster fan content
New York City, 10.22.2025 - ScorePlay, the leading AI-powered MAM/DAM designed for sports, and Wasabi Technologies, the hot cloud storage company, today announced a strategic partnership that redefines how sports organizations manage, collaborate on, and distribute their content. “The future of sports media is open, intelligent, and instant. We’re empowering every organization to harness AI and cloud technology to manage their content with our bespoke industry offering. By removing the traditional barriers of cost and technical complexity, Wasabi and ScorePlay are giving...
22Oct
Sportel: AI changing the game for content creation and fan engagement
The panel, made up of Tixier, Matthew Quinn, vice president of media for English soccer giants Liverpool FC, and cloud storage firm Wasabi Technologies’ chief marketing officer, Michael Welts, discussed how sports organizations were quickly adopting AI into their content strategies in the race to keep fans engaged in different time zones and attract new fans globally. Read More>>
10Oct
In a Major Breakthrough for Cell and Gene Therapy, Immusoft Has Re-dosed a Patient with ISP-001 in Its Lead Program for MPS I
SAN FRANCISCO, Oct. 7, 2025 /PRNewswire/ -- Immusoft of CA, a clinical stage, engineered B cell company, today announced a historic achievement: the safe and well-tolerated re-dosing of a patient with a gene modified therapeutic product candidate. The patient in Immusoft's first-in-human clinical study has now received two doses – separated by 18 months1 – of ISP-001 to treat mucopolysaccharidosis type I (MPS I), with an excellent safety and tolerability profile, to date. Moreover, Immusoft continues to observe positive results in this ongoing...
07Oct
Candidly Launches AI-Powered Financial Guidance Platform
NEW YORK--(BUSINESS WIRE)--Candidly today announced the launch of the Candidly Intelligence Center, an enterprise-grade deterministic AI system that delivers tailored financial insights extensible across multiple financial domains. The Candidly Intelligence Center is a sophisticated multi-agentic backend system that orchestrates specialized AI agents across distinct financial domains that span both the liabilities and assets side of the balance sheet. When combined with a user-facing interface — like Cait, Candidly's conversational AI tool —...
06Oct
Quthero’s Clinical Trial Results Published in Prestigious Medical Journal
TORONTO, ONTARIO, CANADA, September 29, 2025 /EINPresswire.com/ -- Quthero, a pioneering biotech company advancing regenerative medicine through its proprietary Q-peptide platform technology, announced today that the results of their recent clinical trial have been published in the September 2025 issue of the peer-reviewed Journal of Drugs in Dermatology. Quthero's breakthrough technology enables complete regeneration of a patient's natural tissue with minimal scarring. Read More>>
01Oct